The authors analysed data from the Västerbotten Intervention Programme. This community-based programme provided health examinations and questionnaires that collected cardiovascular risk factor data used in the present analysis. The abstract reports standard cardiometabolic variables such as hypertension and diabetes were assessed; however, the abstract did not specify which renal or additional metabolic covariates (for example, serum creatinine, lipid fractions beyond general risk-factor recording) were included in adjusted models. The study team observed associations using the variables reported in the abstract, but detailed covariate lists and modeling decisions were not available in the abstract text.
Phosphatid ethanol 16:0/18:1 (PEth) concentrations were analysed in packed erythrocytes from blood samples collected between 1985 and 2014 and stored at −80 °C until analysis. The cohort included 2,820 individuals. Median age in the sample was 50.2 years and median BMI was 25.9. The highest PEth category (>0.30 μmol/L) was present in 8.9% of participants, and the lowest category reported in the abstract was <0.01 μmol/L. The abstract did not describe the laboratory assay used for measurement, intra-assay variability, or quality-control procedures; those methodological specifics were not provided.
Investigators categorised participants into four PEth groups. Logistic regression models were applied to calculate odds ratios (ORs) with 95% confidence intervals (CIs) for associations between PEth concentrations and arterial cardiovascular risk factors. The abstract documents ORs for comparisons between the high PEth group (>0.30 μmol/L) and the very low group (<0.01 μmol/L). The abstract did not list all covariates included in the regression adjustments, nor did it present model fit indices or sensitivity analyses in the text available.
Data indicated that participants with high PEth (>0.30 μmol/L) had higher odds of established arterial cardiovascular risk factors. Specifically, high PEth was associated with hypertension (OR 1.58; 95% CI 1.14–2.18) and with diabetes (OR 1.89; 95% CI 1.08–3.28) when compared with the reference PEth group (<0.01 μmol/L). These findings are reported as cross-sectional associations derived from logistic regression models. The study team observed these relationships in a middle-aged cohort (median age 50.2 years), but the abstract does not provide stratified analyses by age, sex, or other modifiers beyond those described below.
The cohort showed that high PEth was also associated with demographic and behavioural factors. Male sex had higher odds of elevated PEth (OR 2.58; 95% CI 1.90–3.50). Tobacco exposure, recorded as ever smoking, showed a strong association (OR 5.31; 95% CI 3.75–7.52) with high PEth. Lower education level was likewise associated (OR 2.06; 95% CI 1.32–3.22) compared with the very low PEth group. The authors framed these findings in the context of an unfavourable cardiovascular risk profile accompanying higher biomarker-detected alcohol exposure.
This analysis is cross-sectional. That limits causal inference: investigators reported associations but the design cannot determine whether higher PEth preceded or contributed to the development of hypertension or diabetes. Blood samples were collected over a long period (1985–2014) and stored at −80 °C until analysis; the abstract confirms storage conditions but does not give information on long-term stability testing or potential batch effects. The abstract also omits details on analytic assay characteristics and the full set of covariates included in adjusted models. These gaps reduce the ability to judge residual confounding or measurement bias from the available abstract alone.
The authors concluded that high PEth concentrations were associated with established arterial cardiovascular risk factors and suggested a broader clinical focus when managing patients with elevated PEth. The abstract did not provide data on longitudinal cardiovascular outcomes, clinical thresholds for intervention beyond the PEth categories stated, or the specific screening or management steps they recommend. Absent from the abstract are sensitivity analyses, model specifications, and assay performance metrics; readers seeking those details will need to consult the full text of the article.